
-
Synlogic Inc NasdaqCM:SYBX Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Location: PO Box 30, Winchester, MA, 01890, United States | Website: https://www.synlogictx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-3.82M
Cash
17.27M
Avg Qtr Burn
-4.456M
Short % of Float
0.96%
Insider Ownership
11.31%
Institutional Own.
64.74%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SYNB1353 Details Homocystinuria | Phase 2 Initiation | |
SYNB8802 Details Primary hyperoxaluria | Phase 1 Update | |
Labafenogene marselecobac (previously SYNB1934) Details Phenylketonuria | Failed Discontinued | |
SYNB1891 Details Solid tumor/s, Cancer | Failed Discontinued |